What you need to know to understand Alexey Navalny, one of Vladimir Putin’s loudest critics
How some North Dakota farmers and two former Cheesecake Factory execs are reinventing casual dining
Campaigns to raise the minimum wage are finally coming to fruition
The Salesforce.com CEO is pushing his fellow tech billionaires into giving back to the city
From the U.S. jobless rate to the ruble to pollution in Beijing, here are 10 key indicators that you'll want to keep an eye on
Irate parents find an "extruding tool" for decorating cakes unsavory
Reward points suffer from inflation, too. Here are three strategies for getting the most out of the points you have, before their value falls
"No place to rage quite like the Kasper Multipurpose Room," one student gripes
The Zappos CEO is spending $350 million to build a startup paradise in downtown Las Vegas. It hasn't been all unicorns and butterflies
King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million
Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.
Key to startup success: "We've been able to generate the strong investor support for this idea [because] the technology and the opportunity here is very, very unique, and the possibility of unlocking new areas of biology is so significantly different from what's currently out there."